Plecanatide

CHEMBL2103867 Phase 4 Approuvé Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1681.9 g/mol

LogP

-8.2

Phase

4

Used to treat chronic idiopathic constipation and irritable bowel syndrome with constipation by acting locally in the intestine to increase fluid secretion and speed up bowel movements. It works by activating receptors in the gut lining to soften stools and make them easier to pass.

Masse moléculaire

1681,9000 g/mol

LogP

-8,20

TPSA

819,00 Å²

Règle des 5 de Lipinski

Non conforme

Aires thérapeutiques

Gastroesophageal Reflux Disease

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(C)C[C@H](NC(=O)[C@@H]1CSSC[C@@H]2NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](N)CC(N)=O)CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C(C)C)NC2=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N1)C(=O)O

InChI

InChI=1S/C65H104N18O26S4/c1-25(2)15-34-55(98)80-41-24-113-110-21-38(58(101)77-37(65(108)109)16-26(3)4)71-44(87)20-69-62(105)50(30(10)84)83-61(104)40(78-51(94)29(9)70-63(106)48(27(5)6)81-57(100)35(18-43(68)86)76-64(107)49(28(7)8)82-60(41)103)23-112-111-22-39(59(102)73-32(53(96)75-34)11-13-45(88)89)79-54(97)33(12-14-46(90)91)72-56(99)36(19-47(92)93)74-52(95)31(66)17-42(67)85/h25-41,48-50,84H,11-24,66H2,1-10H3,(H2,67,85)(H2,68,86)(H,69,105)(H,70,106)(H,71,87)(H,72,99)(H,73,102)(H,74,95)(H,75,96)(H,76,107)(H,77,101)(H,78,94)(H,79,97)(H,80,98)(H,81,100)(H,82,103)(H,83,104)(H,88,89)(H,90,91)(H,92,93)(H,108,109)/t29-,30+,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,48-,49-,50-/m0/s1

Molecular Formula

C65H104N18O26S4

HBD / HBA

23 / 31

Liaisons Rotatives

28

Atomes Lourds

113

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

Used to treat chronic idiopathic constipation and irritable bowel syndrome with constipation by acting locally in the intestine to increase fluid secretion and speed up bowel movements. It works by activating receptors in the gut lining to soften stools and make them easier to pass.

Yes, Plecanatide is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2103867. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 70693500. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Plecanatide sur PillFYI

Structure

Données Clés

Formule: C65H104N18O26S4
Synonymes: 1

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.